What is the official ID of this bill?

The official print number for this legislation is HR 1142.

When did the legislative process begin?

The process officially started on 2025-02-07.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/119/bills/hr1142/BILLS-119hr1142ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

Who is the primary sponsor?

The primary sponsor is Rep. Schweikert, David [R-AZ-1].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Analysis and Potential Impact of HR 1142

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

New Medicare Drug Guidelines: Better Adherence and Cheaper Alternatives.

Q: What are the main provisions?

Key points include: Establishment of guidelines to achieve 90% adherence for Medicare Part B and D drugs. Incorporation of artificial intelligence to improve drug adherence. Promotion of generic and biosimilar drugs to reduce costs for patients.

This new bill aims to improve how patients take their Medicare Part B and D drugs. This means citizens can better manage their health and gain easier access to more affordable generic and biosimilar drugs, potentially lowering their treatment costs.

Key points

Establishment of guidelines to achieve 90% adherence for Medicare Part B and D drugs.

Incorporation of artificial intelligence to improve drug adherence.

Promotion of generic and biosimilar drugs to reduce costs for patients.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Introduced

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes.

Print number: HR 1142

Sponsor: Rep. Schweikert, David [R-AZ-1]

Process start date: 2025-02-07

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash

Source data: api.congress.gov

AI work logs for this document launch